Lowering Fecal Immunochemical Test Positivity Threshold vs Multitarget Stool RNA Testing for Colorectal Cancer Screening

Tobias Niedermaier; Teresa Seum; Michael Hoffmeister; Hermann Brenner

doi:10.1001/jama.2024.9289

Back

Lowering Fecal Immunochemical Test Positivity Threshold vs Multitarget Stool RNA Testing for Colorectal Cancer Screening

Article 2024 en

Abstract

1 min read

This analysis uses data from 2 studies to explore whether lowering the threshold for fecal immunochemical test positivity can achieve comparable levels of sensitivity and specificity as multitarget stool RNA testing for colorectal cancer screening.

Discussion(0)

No comments yet. Be the first to comment.

Related publications

Letter2024

Next-Generation Multitarget Stool DNA vs Fecal Immunochemical Test in Colorectal Cancer Screening

Teresa Seum, Tobias Niedermaier, Thomas Heisser, Michael Hoffmeister, Hermann Brenner

Article2025

Cell‐free DNA blood‐based test compared to fecal immunochemical test for colorectal cancer screening

Teresa Seum, Michael Hoffmeister, Hermann Brenner

Editorial Material2024

Making the best use of quantitative fecal immunochemical test results in colorectal cancer screening

Hermann Brenner, Michael Hoffmeister

Article2025

Diagnostic performance of a circulating tumor DNA‐based blood test compared to fecal immunochemical test in colorectal cancer screening

Hermann Brenner, Teresa Seum, Megha Bhardwaj, Michael Hoffmeister

Preprint2021

Serum methylation of GALNT9, UPF3A, WARS, and LDB2 as non-invasive biomarkers for the early detection of colorectal cancer and premalignant adenomas

María Gallardo‐Gómez, Mar Rodríguez‐Girondo, Núria Planell, Sebastián Morán, Luís Bujanda, Ane Etxart, Antoni Castells, Francesc Balaguer, Rodrigo Jover, Manel Esteller, Joaquín Cubiella, David Gómez-Cabrero, Loretta De Chiara

Lowering Fecal Immunochemical Test Positivity Threshold vs Multitarget Stool RNA Testing for Colorectal Cancer Screening

Abstract

Discussion(0)

Related publications

Next-Generation Multitarget Stool DNA vs Fecal Immunochemical Test in Colorectal Cancer Screening

Cell‐free DNA blood‐based test compared to fecal immunochemical test for colorectal cancer screening

Making the best use of quantitative fecal immunochemical test results in colorectal cancer screening

Diagnostic performance of a circulating tumor DNA‐based blood test compared to fecal immunochemical test in colorectal cancer screening

Serum methylation of <i>GALNT9</i>, <i>UPF3A</i>, <i>WARS,</i> and <i>LDB2</i> as non-invasive biomarkers for the early detection of colorectal cancer and premalignant adenomas